In the long effort to understand why cancer so often finds its way to bone, researchers at Baylor College of Medicine have uncovered a molecular culprit hiding in plain sight: the loss of a single tumor suppressor gene, NF1, present in nearly two-thirds of metastatic estrogen receptor-positive breast cancer cases. When this gene fails, cancer cells do not simply grow faster — they rewrite their environment, corrupting bone tissue and silencing the immune system in tandem. The discovery, published in Cancer Letters, suggests that the half-million lives lost each year to metastatic ER+ breast ca
NF1 Loss Links ER+ Breast Cancer to Bone Metastasis Through Immune Suppression
ER+ breast cancer metastasis accounts for approximately 500,000 deaths globally annually, with bone metastasis being the primary cause of death in this population.
Cancer destroys bone, and the damaged bone nourishes the cancer
Mark
Why does NF1 loss specifically drive cancer toward bone rather than, say, the lungs or liver?
Mimi
That's the question the team is still working to fully answer. But the clue is in what NF1-deficient cells can do—they express genes normally active in bone cells themselves. It's as if the cancer cells are learning to speak the language of bone, making themselves compatible with that environment in a way they wouldn't be elsewhere.
Mark
So the cancer is essentially disguising itself as bone?
Mimi
Not quite disguising—more like adapting. The cells are triggering bone breakdown, which releases growth factors. They're also suppressing the immune cells that would normally patrol bone tissue. It's a two-pronged strategy: make the environment hostile to immune attack and rich with nutrients.
Mark
The 62 percent figure is striking. That's not rare.
Mimi
Exactly. This isn't a curiosity found in a handful of patients. It's a common feature of metastatic ER+ breast cancer. That's why it matters clinically. If you can identify it, you can potentially act on it.
Mark
What would acting on it look like?
Mimi
Right now, ER+ breast cancer is treated with hormone therapy—drugs that block estrogen signaling. But if NF1 is lost, those cells become resistant. The research suggests you might need to add therapies that either restore immune function or block the bone-remodeling process that feeds the cancer.
Mark
Is that being tested now?
Mimi
The paper doesn't say they've moved to clinical trials yet. But the findings make a strong case for why such trials should happen. They've identified a mechanism. Now comes the harder work of proving it works in patients.
O Pulso
- NF1 loss — found in 62% of metastatic ER+ breast cancer patients — is not a rare anomaly but a defining feature of the disease at its most lethal stage.
- When NF1 fails, cancer cells hijack the bone's own demolition machinery, triggering osteoclasts to destroy bone and release stored growth factors that loop back to feed the tumor.
- Simultaneously, NF1-deficient tumors drain the immune system's defenses, exhausting the T cells that would otherwise hunt and kill cancer cells.
- These twin mechanisms — bone corruption and immune suppression — combine to make the skeleton a fortress for cancer rather than a site of resistance.
- The findings point toward NF1 status as a potential clinical biomarker, opening the door to targeted therapies that could disrupt bone remodeling, restore immune function, or directly address NF1-related pathways.
In the long effort to understand why cancer so often finds its way to bone, researchers at Baylor College of Medicine have uncovered a molecular culprit hiding in plain sight: the loss of a single tumor suppressor gene, NF1, present in nearly two-thirds of metastatic estrogen receptor-positive breast cancer cases. When this gene fails, cancer cells do not simply grow faster — they rewrite their environment, corrupting bone tissue and silencing the immune system in tandem. The discovery, published in Cancer Letters, suggests that the half-million lives lost each year to metastatic ER+ breast cancer may be shaped less by fate than by a specific, identifiable, and potentially targetable genetic event.
Researchers at Baylor College of Medicine have identified a molecular mechanism explaining why certain breast cancers spread to bone — a discovery that could change how doctors approach the disease's most common form.
The gene at the center of the story is NF1, a tumor suppressor. When it is lost or damaged in estrogen receptor-positive breast cancer cells — which account for more than 70 percent of all breast cancers — the consequences are far-reaching. Affected cells develop a pull toward bone, grow resistant to standard hormone therapies, and begin undermining the body's own immune defenses. NF1 loss is not rare in this context: roughly 62 percent of patients with metastatic ER+ breast cancer show evidence of it. With metastasis responsible for approximately 500,000 deaths globally each year, understanding what drives that spread matters enormously.
Dr. Eric C. Chang and his team identified two distinct mechanisms. The first is structural: NF1-deficient cancer cells begin expressing bone-cell genes and triggering osteoclasts — the cells that break down bone — into overdrive. The resulting destruction releases growth factors stored in bone tissue, which then cycle back to nourish the tumor. Cancer destroys bone; damaged bone feeds the cancer.
The second mechanism is immunological. Tumor samples from patients with low NF1 levels contained fewer active CD8+ T cells, and those present showed signs of exhaustion — a state in which immune cells lose their capacity to fight. Laboratory experiments confirmed that NF1-deficient cancer cells actively suppressed T-cell activity and interfered with engineered immune therapies.
Together, these effects transform bone into a hospitable environment for cancer while dismantling the defenses that might otherwise contain it. The clinical implications are significant: NF1 status could become a biomarker guiding treatment selection, pointing patients toward therapies targeting bone remodeling, immune restoration, or NF1-related pathways — and suggesting that precision oncology may need to look beyond broad receptor categories toward the specific genetic damage shaping each tumor's behavior.
Researchers at Baylor College of Medicine have identified a molecular mechanism that explains why certain breast cancers spread to bone—and the discovery could reshape how doctors select treatments for the disease's most common form.
The work centers on a tumor suppressor gene called NF1. When this gene is lost or damaged in estrogen receptor-positive breast cancer cells—the kind that accounts for more than 70 percent of all breast cancers—something shifts. The cells begin to behave differently. They develop an affinity for bone. They become harder to kill with standard hormone therapy. And they suppress the body's own immune defenses against cancer. The findings appear in Cancer Letters.
The scale of the problem is substantial. Among patients with metastatic ER+ breast cancer, about 62 percent show evidence of NF1 loss. That's not a rare mutation. It's a common feature of the disease in its most dangerous form. Metastasis—the spread of cancer beyond the original tumor—remains the primary cause of death in ER+ breast cancer, accounting for roughly half a million deaths worldwide each year. Understanding what drives that spread to bone specifically could alter survival rates.
The research team, led by Dr. Eric C. Chang, discovered two distinct mechanisms at work. The first involves bone itself. When NF1 is lost, the cancer cells begin expressing genes normally found in bone cells. They trigger the development of osteoclasts—specialized cells whose job is to break down bone tissue. This excessive bone destruction releases growth factors that have been stored in the bone matrix. Those factors then feed back to stimulate the cancer's growth. It becomes a vicious cycle: cancer destroys bone, and the damaged bone nourishes the cancer in return.
The second mechanism is immunological. When researchers analyzed tumor samples from patients, they found that tumors with low NF1 levels contained fewer active CD8+ T cells—the immune system's primary cancer-fighting soldiers. The T cells that were present showed signs of exhaustion, a state in which they lose their ability to attack cancer. Laboratory experiments confirmed the mechanism: NF1-deficient cancer cells actively suppressed T-cell proliferation, reduced the production of immune signaling molecules, and made it harder for engineered cancer-killing T cells to do their job.
Together, these two effects—bone remodeling and immune suppression—create an environment where cancer can establish itself and flourish within the skeleton. The cancer essentially rewrites the rules of its surroundings, making bone a hospitable place to grow while simultaneously disarming the immune system that might otherwise contain it.
The implications are clinical as well as biological. If NF1 status can reliably identify patients at higher risk of bone metastasis, it could become a biomarker that guides treatment decisions. Patients with NF1-deficient tumors might benefit from therapies that target bone remodeling, boost immune function, or directly interfere with NF1-related pathways—approaches that might not help patients whose cancers retain functional NF1. The work suggests that precision medicine in breast cancer treatment may depend less on broad categories like hormone receptor status and more on the specific genetic damage that shapes how individual tumors behave.
Citações Notáveis
Loss of NF1 allows ER+ breast cancer cells to remodel their environment in ways that favor their survival and growth by simultaneously promoting bone destruction and suppressing antitumor immunity.— Dr. Eric C. Chang, Baylor College of Medicine
Quer a matéria completa?
Leia o original em Medical Xpress ↗
Education